Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
kBg9sfaPg0gJv8CQ
Listen
